Peregrine Pharma (PPHM) Reports In-Line Q1 Loss

Peregrine Pharma (NASDAQ: PPHM) reported Q1 EPS of ($0.08), in-line with the analyst estimate of ($0.08). Revenue for the quarter came in at $9.67 million versus the consensus estimate of $7.03 million.

For earnings history and earnings-related data on Peregrine Pharma (PPHM) click here.

You May Also Be Interested In

• Rivian reports record Q3 deliveries, beats estimates, shares rise
• First Watch (FWRG) PT Lowered to $15 at DA Davidson, Buy Rating Maintained
• Onto Innovation gains on bullish RBC initiation citing advanced packaging growth